194 related articles for article (PubMed ID: 23249204)
1. Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.
Oliveira AI; Jerónimo C; Henrique R
Expert Rev Mol Diagn; 2012 Nov; 12(8):871-8. PubMed ID: 23249204
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
5. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples.
Costa VL; Henrique R; Danielsen SA; Duarte-Pereira S; Eknaes M; Skotheim RI; Rodrigues A; Magalhães JS; Oliveira J; Lothe RA; Teixeira MR; Jerónimo C; Lind GE
Clin Cancer Res; 2010 Dec; 16(23):5842-51. PubMed ID: 20975101
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
[TBL] [Abstract][Full Text] [Related]
8. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.
Kamat AM; Hegarty PK; Gee JR; Clark PE; Svatek RS; Hegarty N; Shariat SF; Xylinas E; Schmitz-Dräger BJ; Lotan Y; Jenkins LC; Droller M; van Rhijn BW; Karakiewicz PI;
Eur Urol; 2013 Jan; 63(1):4-15. PubMed ID: 23083902
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer: translating molecular genetic insights into clinical practice.
Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
[TBL] [Abstract][Full Text] [Related]
10. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
[TBL] [Abstract][Full Text] [Related]
11. [Non-invasive molecular detection of bladder cancer].
Hatachmi S
Harefuah; 2009 Jan; 148(1):66-9, 86. PubMed ID: 19320394
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in bladder cancer diagnostics.
Sanchez-Carbayo M
Clin Biochem; 2004 Jul; 37(7):562-71. PubMed ID: 15234237
[TBL] [Abstract][Full Text] [Related]
14. Urine epigenomics: a promising path for bladder cancer diagnostics.
Sánchez-Carbayo M
Expert Rev Mol Diagn; 2012 Jun; 12(5):429-32. PubMed ID: 22702358
[No Abstract] [Full Text] [Related]
15. Epigenetic biomarkers in cancer epidemiology.
Verma M
Methods Mol Biol; 2012; 863():467-80. PubMed ID: 22359311
[TBL] [Abstract][Full Text] [Related]
16. Current status of molecular markers for prognostication and outcome in invasive bladder cancer.
Gakis G; Schwentner C; Todenhöfer T; Stenzl A
BJU Int; 2012 Jul; 110(2):233-7. PubMed ID: 22233187
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
18. Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder.
Sapre N; Herle P; Anderson PD; Corcoran NM; Hovens CM
Pathology; 2014 Jun; 46(4):274-82. PubMed ID: 24798156
[TBL] [Abstract][Full Text] [Related]
19. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
20. The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer.
Gonzalgo ML; Datar RH; Schoenberg MP; Cote RJ
Urol Oncol; 2007; 25(3):228-35. PubMed ID: 17483020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
